Citation:Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011

From Cancer Guidelines Wiki

Citation


Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology 2011 Nov;16(8):1210-20 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/21801275.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
  3. What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC